Regulatory SubmissionSENDSensible SEND
Virtual Control Groups: Divisive Innovation With SEND
Marc Ellison
The proliferation of standardized nonclinical data has paved the way for us to explore new ways to reuse and repurpose existing study data.
SEND Blog
Regulatory SubmissionSENDSensible SEND
Will AI steal my SEND job?
Marc Ellison
AI has clear uses in fraud detection, cybersecurity, and supply chain management, and seems to be used in innovative applications across various industries but does it have an application for SEND?
BiotechCROPharmaceuticalPre-ClinicalRegulatory ComplianceRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND
We need to talk about SEND v4.0
Marc Ellison
Due to be published in 2026, SEND 4.0 is the next update due for the SEND standard.
BiotechCentrusCROData IntegrationDiscoveryDrug DiscoveryPharmaceuticalPre-ClinicalRegulatory SubmissionSENDSensible SEND
It’s Raining Data! Navigating the Data Cycle
Marc Ellison
In this ever-evolving ecosystem, the key to unlocking a future rich in insights and possibilities is to harness the power of the data cycle.
BiotechCROCyto Study ManagerPharmaceuticalPre-ClinicalRegulatory ComplianceRegulatory SubmissionSENDSEND Advantage ServicesSensible SENDSubmit
So, what’s happening in SEND?
Marc Ellison
Aside from implementation of the Genetox IG, the other main activity that is currently advancing is SEND v4.0.
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
The Hot SEND Topics from ACT 2023
Marc Ellison
People are now more focused on the uses of SEND beyond submission, as well as seeing the scope of SEND widening further as we close out the year.
Stay up to Date
Get expert tips, industry news, and fresh content delivered to your inbox.
